First-line therapy approval for crizotinib was given in 2017 based on ASCEND-1 and ASCEND-2 studies [76, 77], with the latter accomplishing a 38.6% ORR to crizotinib pretreated ALK + NSCLC, via 750 mg daily intake [77]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.